Arcus Biosciences Inc.
RCUS | NYSE
$26.28
+$0.33 (+1.27%)
Sep 22, 2026, 10:47 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 247M | 258M | 117M | 112M | 383M | 78M |
Cost of Revenue | 10M | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 237M | 258M | 117M | 112M | 383M | 78M |
Operating Income | -386M | -330M | -340M | -280M | 54M | -124M |
Interest Income | 41M | 52M | 41M | 16M | 1M | 1M |
Pretax Income | -353M | -283M | -301M | -266M | 55M | -123M |
Net Income | -353M | -283M | -307M | -267M | 53M | -123M |
Selling & General & Admin | 110M | 120M | 117M | 104M | 72M | 43M |
Research & Development | 523M | 448M | 340M | 288M | 257M | 159M |
Other Expenses | -10M | 20M | n/a | n/a | n/a | n/a |
Operating Expenses | 623M | 588M | 457M | 392M | 329M | 202M |
Interest Expense | 8M | 4M | 2M | 2M | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 633M | 588M | 457M | 392M | 329M | 202M |
Income Tax Expense | n/a | 1M | 6M | 1M | 2M | n/a |
Shares Outstanding (Basic) | 107.4M | 90.1M | 74M | 72M | 69.35M | 54.79M |
Shares Outstanding (Diluted) | 107.4M | 90.1M | 74M | 72M | 73.97M | 54.79M |
EPS (Basic) | -3.29 | -3.14 | -4.15 | -3.71 | 0.76 | -2.13 |
EPS (Diluted) | -3.29 | -3.14 | -4.15 | -3.71 | 0.71 | -2.13 |
EBITDA | -335M | -269M | -291M | -258M | 59M | -120M |
EBIT | -345M | -279M | -299M | -264M | 55M | -123M |
Depreciation & Amortization | 10M | 10M | 8M | 6M | 4M | 3M |
Add to Watchlist
Select watchlists to add or remove RCUS